INFLIXIMAB TROUGH LEVELS AND DISEASE ACTIVITY PREDICT EARLY CLINICAL RESPONSE IN PATIENTS WITH AXIAL SPONDYLOARHTRITIS

被引：2

作者：

Martinez-Feito, Ana ^{[1
]}

Plasencia, Chamaida ^{[2
]}

Hernandez-Breijo, Borja ^{[3
]}

Navarro-Compan, Victoria ^{[2
]}

Peiteado, Diana ^{[2
]}

Villalva, Alejandro ^{[2
]}

Nuno, Laura ^{[2
]}

Monjo, Irene ^{[2
]}

Diego, Cristina ^{[1
]}

Pascual-Salcedo, Dora ^{[3
]}

Balsa, Alejandro ^{[2
]}

机构：

[1] Hosp La Paz Madrid, Immunol, Madrid, Spain

[2] Hosp La Paz Madrid, Rheumatol, Madrid, Spain

[3] IdiPAZ, Immunorheumatol Res Grp, Madrid, Spain

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2019年 / 78卷

关键词：

D O I：

10.1136/annrheumdis-2019-eular.3984

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

FRI0399

引用

页码：885 / 885

页数：1

共 50 条

[1] Infliximab Serum Trough Levels Predict Non-clinical Response in Patients with Axial Spondyloarthritis
Plasencia, Chamaida
Martinez-Feito, Ana
Hernandez-Breijo, Borja
Navarro-Compan, Victoria
Olariaga-Merida, Eva
Peiteado, Diana
Villalba, Alejandro
Monjo, Irene
Nuno, Laura
Diego, Cristina
Pascual-Salcedo, Dora
Balsa, Alejandro
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[2] Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease
Bortlik, Martin
Duricova, Dana
Malickova, Karin
Machkova, Nadezda
Bouzkova, Eva
Hrdlicka, Ludek
Komarek, Arnost
Lukas, Milan
JOURNAL OF CROHNS & COLITIS, 2013, 7 (09): : 736 - 743
[3] Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease
Pariente, Benjamin
de Chambrun, Guillaume Pineton
Krzysiek, Roman
Desroches, Marine
Louis, Gauthier
De Cassan, Chiara
Baudry, Clotilde
Gornet, Jean-Marc
Desreumaux, Pierre
Emilie, Dominique
Colombel, Jean-Frederic
Allez, Matthieu
INFLAMMATORY BOWEL DISEASES, 2012, 18 (07) : 1199 - 1206
[4] Early infliximab trough levels in paediatric IBD patients predict sustained remission
Bevers, Nanja
Aliu, Arta
Wong, Dennis R.
Winkens, Bjorn
Vreugdenhil, Anita
Pierik, Marieke J.
Derijks, Luc J. J.
van Rheenen, Patrick F.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2024, 17
[5] Early infliximab trough levels in paediatric IBD patients predict sustained remission
Bevers, N.
Aliu, A.
Wong, D.
Derijks, L.
Winkens, B.
Vreugdenhil, A.
Pierik, M.
Van Rheenen, P.
JOURNAL OF CROHNS & COLITIS, 2023, 17 : 581 - 582
[6] Low Infliximab Trough Levels Are Not Predictive of Disease Activity in Clinical Practice
Jeyarajah, Shivashini Kirthi
Hall, Barry
Hussey, Mary
Gilmer, John
Wang, Jun
Medina, Carlos
McNamara, Deirdre
GASTROENTEROLOGY, 2015, 148 (04) : S856 - S856
[7] Early Infliximab Trough Levels Predict Remission at one Year in Pediatric IBD Patients
Rosenthal, Casey
Melmed, Gil
Tripuraneni, Bhavna
Gebbia, Jennifer
Callejas, Silvia
Farrior, Sharmayne
Rabizadeh, Shervin
Dubinsky, Marla
INFLAMMATORY BOWEL DISEASES, 2012, 18 : S5 - S5
[8] Early Infliximab Trough Levels Predict Remission at One Year in Pediatric IBD Patients
Rosenthal, Casey
Melmed, Gil
Tripuraneni, Bhavna
Gebbia, Jennifer
Callejas, Silvia
Farrior, Sharmayne
Rabizadeh, Shervin
Dubinsky, Marla
INFLAMMATORY BOWEL DISEASES, 2012, 18 : S81 - S81
[9] Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy
Baert, Filip
Drobne, David
Gils, Ann
Vande Casteele, Niels
Hauenstein, Scott
Singh, Sharat
Lockton, Steve
Rutgeerts, Paul
Vermeire, Severine
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2014, 12 (09) : 1474 - U352
[10] Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease
Merras-Salmio, Laura
Kolho, Kaija-Leena
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2017, 64 (02): : 272 - 278

← 1 2 3 4 5 →